ArticleJournal of translational medicine2025
Effects of combined high-sensitivity C-reactive protein and residual cholesterol levels on new-onset diabetes: evidence from two prospective cohort studies.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between non-traditional lipid-inflammatory parameters and incident diabetes: a national prospective cohort study.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHigh-sensitivity C-reactive protein (hsCRP) and residual cholesterol (RC) have been pinpointed as potential diabetes risk factors. Nonetheless, the combined impact of these biomarkers on the incidence of diabetes is still unclear. The objective of this analysis is to explore the joint effects of RC and hsCRP on the incidence of new diabetes.
methodsWe analyzed 9,309 individuals in the China Health and Retirement Longitudinal Study (CHARLS) and 4,743 participants in the English Longitudinal Study of Ageing (ELSA), all of whom had no history of diabetes at baseline. To examine the joint effect of RC and hsCRP on diabetes risk, individuals were sorted into four groups based on median RC levels and an hsCRP threshold of 1 mg/L. To comprehensively assess the effects of RC and hsCRP on diabetes, a Residual Cholesterol-Inflammation Index (RCII) was established. Cox proportional hazards regression analysis and mediation analysis were conducted.
resultsFollowing comprehensive adjustments, individuals with elevated hsCRP alone, elevated RC alone, and both elevated hsCRP and RC demonstrated progressively increased risks of diabetes relative to those with low levels of hsCRP and RC across two databases. Multivariate analyses demonstrated that subjects in the highest quartile of RCII experienced a 79% increased likelihood of diabetes in CHARLS and a 99% increase in ELSA, relative to those in the lowest quartile of RCII. In the relationship between RC and diabetes, hsCRP acts as a mediator, accounting for 4.8% of the effect in CHARLS and 5.1% in ELSA. Conversely, in the relationship between hsCRP and diabetes, RC mediates 12.7% of the impact in CHARLS and 10.5% in ELSA.
conclusionOur findings demonstrate the joint and mediating impacts of RC and hsCRP in diabetes risk assessment. Consequently, we recommend assessing both RC and hsCRP levels together and taking further steps to reduce the risk of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.